Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an 'Outperform' rating for Adicet Bio (NASDAQ:ACET) and maintained a price target of $5.
September 20, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an 'Outperform' rating for Adicet Bio and maintained a price target of $5, indicating confidence in the company's future performance.
The reiteration of an 'Outperform' rating and maintenance of a $5 price target by Wedbush suggests positive sentiment and confidence in Adicet Bio's future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100